(-2% ± 5) DIII. As expected, E16, which only weakly recognizes K307N, poorly competed (Fab 6% ± 3; IgG 9% ± 4) binding to K307N DIII. These data suggest that humans, who clear WNV infection, develop antibodies that recognize an epitope in close proximity to that defined by E16.